Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease

Feresiadou, Amalia; Nilsson, Kenneth; Ingelsson, Martin; Kmezic, Ivan; Nygren, Ingela; Svenningsson, Anders; Niemelä, Valter; Gordh, Torsten; Cunningham, Janet L.; Kultima, Kim; Larsson, Anders; Burman, Joachim

doi:10.1016/j.jneuroim.2019.03.015

Cited by 12 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CSF from matched controls was obtained from a biobank at the same clinic consisting of patients who had undergone lumbar puncture for investigation purposes and in whom neurological disease had been ruled out. The procedure was similar to that of the HD sample collection and has been published before 18 . Controls were selected according to the following exclusion criteria: previously known disorder of the central nervous system (CNS); investigation that resulted in a CNS disorder (inflammatory, degenerative, or infectious) or other significant medical diagnosis (eg, cancer); significantly abnormal standard analyses of CSF (eg, cells, albumin, glucose, and lactate) or other CSF analyses (where available); and significant neuroradiological abnormalities (where available).…”

Section: Methodsmentioning

confidence: 99%

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objective Identifying molecular changes that contribute to the onset and progression of Huntington's disease (HD) is of importance for the development and evaluation of potential therapies. Methods We conducted an unbiased mass‐spectrometry proteomic analysis on the cerebrospinal fluid of 12 manifest HD patients (ManHD), 13 pre‐manifest (preHD), and 38 controls. A biologically plausible and significant possible biomarker was validated in samples from a separate cohort of patients and controls consisting of 23 ManHD patients and 23 controls. Results In ManHD compared to preHD, 10 proteins were downregulated and 43 upregulated. Decreased levels of proenkephalin (PENK) and transthyretin were closely linked to HD symptom severity, whereas levels of 15 upregulated proteins were associated with symptom severity. The decreased PENK levels were replicated in the separate cohort where absolute quantitation was performed. Conclusions We hypothesize that declining PENK levels reflect the degeneration of medium spiny neurons (MSNs) that produce PENK and that assays for PENK may serve as a surrogate marker for the state of MSNs in HD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

show abstract

Section: Methodsmentioning

confidence: 99%

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…We identified inflammatory markers, sCD27 and CCL4, as candidates for further investigation. sCD27 is elevated in a wide range of neuroinflammatory states and autoimmune diseases [50][51][52][53][54][55][56][57] . sCD27 dynamics in the cases may reflect central vs peripheral inflammatory states that responded to treatment.…”

Section: Discussionmentioning

confidence: 99%

Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment

Cunningham,

Gallwitz,

Lindqvist

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Obsessive compulsive disorder (OCD) is a debilitating condition affecting about 2% of the population where half of patients do not respond to standard treatment. The emerging concept of an autoimmune OCD subgroup is grounded on findings that suggest immunological aetiology. We here present the longitudinal clinical course for three severely ill, functionally impaired complex cases with chronic treatment-resistant OCD. In all three cases, off-label treatment with rituximab was followed by clear and sustained gains regarding symptom burden and function over several years. The clinical phenotypes and clinical red flags are described in detail. Antibodies targeting mouse brain tissue were detected in cerebral spinal fluid for all three cases. We report exploratory analyses of immunological markers and proteomics and findings include elevated levels of sCD27 and markers indicative for complement pathway activation in CSF when compared to controls. Multidisciplinary collaboration, advanced clinical investigations and rituximab treatment are feasible in a psychiatric setting. The case histories provide a proof of principle for the newly proposed criteria for autoimmune OCD. The findings suggest that clinical red flags and biological measures may predict rituximab response in chronic treatment-resistant OCD. The report provides orientation that may inform the hypotheses and design of future treatment trials.

show abstract

“… 14 , 16 , 17 More in general, two studies have concluded that CSF sCD27 assays could discriminate between inflammatory and non-inflammatory neurological disorders, which can substantially assist the diagnosing process in this complex area of diseases. 8 , 18 …”

Section: Introductionmentioning

confidence: 99%

Cerebrospinal fluid and plasma concentrations of the inflammatory marker soluble CD27 in a large surgical population

Tigchelaar,

Cunningham,

Rasmusson

et al. 2024

iScience

Self Cite

View full text Add to dashboard Cite

Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease

Cited by 12 publications

References 20 publications

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease

Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment

Cerebrospinal fluid and plasma concentrations of the inflammatory marker soluble CD27 in a large surgical population

Contact Info

Product

Resources

About